LENZ (LENZ Therapeutics) EBITDA Margin %: -2,315.83% (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.51
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics EBITDA Margin %?

LENZ Therapeutics LENZ -1.25% 12 EBITDA Margin % is -2,315.83% as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, LENZ Therapeutics ranks worse than 72.78% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LENZ Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-44.02 Mil. LENZ Therapeutics's Revenue for the three months ended in Mar. 2026 was $1.90 Mil. Therefore, LENZ Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -2,315.83%.

LENZ Therapeutics  (NAS:LENZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

LENZ Therapeutics EBITDA Margin % Related Terms

LENZ Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics EBITDA Margin % Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 -69.83 0.00 0.00 -475.96

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -336.76 -150.10 -2,415.37 -2,315.83

LENZ vs CNXU, CHRS, SLGL: EBITDA Margin % Comparison

For the Biotechnology subindustry, LENZ Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENZ Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's EBITDA Margin % falls into.


LENZ
12GF Score
LENZ Therapeutics Inc LENZ
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LENZ Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-90.851/19.088
=-475.96 %

LENZ Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-44.024/1.901
=-2,315.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -2,315.83% mean?
LENZ Therapeutics (LENZ) has a EBITDA Margin % of -2,315.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LENZ Therapeutics and its competitors. According to the industry distribution chart, LENZ Therapeutics ranks #687 out of 944 companies in the Biotechnology industry, placing it in the top 72.8%.
Is LENZ Therapeutics' EBITDA Margin % too high?
LENZ Therapeutics' current EBITDA Margin % is -2,315.83%. Based on the distribution chart, LENZ Therapeutics ranks #687 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' EBITDA Margin % compare to CNXU and CHRS?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #687 out of 944 companies for EBITDA Margin %. This places LENZ Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current EBITDA Margin % is -2,315.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current EBITDA Margin % of -2,315.83%. The current EBITDA Margin % is -2,315.83%. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current EBITDA Margin % is -2,315.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.51
Price